Soleno Therapeutics, Inc. (SLNO)

Market Cap	3.64B
Revenue (ttm)	32.66M
Net Income (ttm)	-181.08M
Shares Out	53.15M
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	52.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	762,246
Open	67.76
Previous Close	67.68
Day's Range	67.68 - 69.42
52-Week Range	41.50 - 90.32
Beta	-2.56
Analysts	Strong Buy
Price Target	112.50 (+64.45%)
Earnings Date	Aug 6, 2025

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Summary

According to 10 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price target is $112.5, which is an increase of 64.45% from the latest price.

Price Target

$112.5

(64.45% upside)

Analyst Consensus: Strong Buy